BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ortiz Zacarías NV, Bemelmans MP, Handel TM, de Visser KE, Heitman LH. Anticancer opportunities at every stage of chemokine function. Trends Pharmacol Sci 2021;42:912-28. [PMID: 34521537 DOI: 10.1016/j.tips.2021.08.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 den Hollander LS, Béquignon OJM, Wang X, van Wezel K, Broekhuis J, Gorostiola González M, de Visser KE, IJzerman AP, van Westen GJP, Heitman LH. Impact of cancer-associated mutations in CC chemokine receptor 2 on receptor function and antagonism. Biochem Pharmacol 2023;208:115399. [PMID: 36581051 DOI: 10.1016/j.bcp.2022.115399] [Reference Citation Analysis]
2 Tran TT, Tran QH, Duong CQ, Nguyen QT, Tran VT, Le MT, Tran VH, Thai KM. In silico approach to identify novel allosteric intracellular antagonist for blocking the interleukin-8/CXCR2 receptor signaling pathway. J Biomol Struct Dyn 2023;:1-14. [PMID: 36709441 DOI: 10.1080/07391102.2023.2171136] [Reference Citation Analysis]
3 Yang Y, Fu X, Liu R, Yan L, Yang Y. Exploring the prognostic value of HK3 and its association with immune infiltration in glioblastoma multiforme. Front Genet 2022;13:1033572. [PMID: 36712881 DOI: 10.3389/fgene.2022.1033572] [Reference Citation Analysis]
4 Torphy RJ, Yee EJ, Schulick RD, Zhu Y. Atypical chemokine receptors: emerging therapeutic targets in cancer. Trends Pharmacol Sci 2022;43:1085-97. [PMID: 36307250 DOI: 10.1016/j.tips.2022.09.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Deng J, Jiang R, Meng E, Wu H. CXCL5: A coachman to drive cancer progression. Front Oncol 2022;12:944494. [DOI: 10.3389/fonc.2022.944494] [Reference Citation Analysis]
6 Srivastava S, Mohanty A, Nam A, Singhal S, Salgia R. Chemokines and NSCLC: Emerging role in prognosis, heterogeneity, and therapeutics. Semin Cancer Biol 2022:S1044-579X(22)00154-7. [PMID: 35787939 DOI: 10.1016/j.semcancer.2022.06.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Tian Z, Hong B, Chen J, Tang Z. Combination of Radiofrequency Ablation With Resiquimod to Treat Hepatocellular Carcinoma Via Inflammation of Tumor Immune Microenvironment and Suppression of Angiogenesis. Front Oncol 2022;12:891724. [PMID: 35719978 DOI: 10.3389/fonc.2022.891724] [Reference Citation Analysis]
8 Masih M, Agarwal S, Kaur R, Gautam PK. Role of chemokines in breast cancer. Cytokine 2022;155:155909. [PMID: 35597171 DOI: 10.1016/j.cyto.2022.155909] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
9 Pang L, Khan F, Dunterman M, Chen P. Pharmacological targeting of the tumor–immune symbiosis in glioblastoma. Trends in Pharmacological Sciences 2022. [DOI: 10.1016/j.tips.2022.04.002] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Gilchrist A, Echeverria SL. Targeting Chemokine Receptor CCR1 as a Potential Therapeutic Approach for Multiple Myeloma. Front Endocrinol (Lausanne) 2022;13:846310. [PMID: 35399952 DOI: 10.3389/fendo.2022.846310] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Billen M, Schols D, Verwilst P. Targeting chemokine receptors from the inside-out: discovery and development of small-molecule intracellular antagonists. Chem Commun (Camb) 2022;58:4132-48. [PMID: 35274633 DOI: 10.1039/d1cc07080k] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Wang Y, Fang Y, Zhao F, Gu J, Lv X, Xu R, Zhang B, Fang Z, Li Y. Identification of GGT5 as a Novel Prognostic Biomarker for Gastric Cancer and its Correlation With Immune Cell Infiltration. Front Genet 2022;13:810292. [DOI: 10.3389/fgene.2022.810292] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Schlecht-Louf G, Deback C, Bachelerie F. The Chemokine System in Oncogenic Pathways Driven by Viruses: Perspectives for Cancer Immunotherapy. Cancers (Basel) 2022;14:848. [PMID: 35159113 DOI: 10.3390/cancers14030848] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Isaikina P, Tsai C, Petrovic I, Rogowski M, Dürr AM, Grzesiek S. Preparation of a stable CCL5·CCR5·Gi signaling complex for Cryo-EM analysis. Biomolecular Interactions Part B 2022. [DOI: 10.1016/bs.mcb.2022.03.001] [Reference Citation Analysis]
15 Borroni EM, Grizzi F. Cancer Immunoediting and beyond in 2021. Int J Mol Sci 2021;22:13275. [PMID: 34948072 DOI: 10.3390/ijms222413275] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]